Antipsychotics in Children and Adolescents at Clinical High Risk for Psychosis

The prescription of antipsychotics in young children and adolescents is a delicate, complex, and often divisive issue, where official guidelines and real-world prescriptive habits seldom correspond.1 Such discrepancy is even more radical and excruciating in those conditions with an established higher risk of imminent development of an overt psychotic state (ie, Clinical High Risk for Psychosis [CHR-P] and the related diagnostic construct of DSM-5 Attenuated Psychosis Syndrome [APS]) that fall below the severity threshold for a DSM-5 diagnosis of schizophrenia and other psychotic disorders.